Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Katja, Conrath"'
Autor:
Eyleen de Poel, Sacha Spelier, Ricardo Korporaal, Ka Wai Lai, Sylvia F. Boj, Katja Conrath, Cornelis K. van der Ent, Jeffrey M. Beekman
Publikováno v:
Frontiers in Molecular Biosciences, Vol 8 (2021)
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have transformed the treatment of cystic fibrosis (CF) by targeting the basis of the disease. In particular, treatment regimen consisting of multiple compounds with complementary m
Externí odkaz:
https://doaj.org/article/c3728af76f74411abfc3fd345775fa10
Autor:
Gert de Wilde, Maarten Gees, Sara Musch, Katleen Verdonck, Mia Jans, Anne-Sophie Wesse, Ashvani K. Singh, Tzyh-Chang Hwang, Thierry Christophe, Mathieu Pizzonero, Steven Van der Plas, Nicolas Desroy, Marlon Cowart, Pieter Stouten, Luc Nelles, Katja Conrath
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
The deletion of phenylalanine at position 508 (F508del) in cystic fibrosis transmembrane conductance regulator (CFTR) causes a severe defect in folding and trafficking of the chloride channel resulting in its absence at the plasma membrane of epithel
Externí odkaz:
https://doaj.org/article/8d68380c55104f5f99c3962f9d0c136b
Autor:
Maarten Gees, Sara Musch, Steven Van der Plas, Anne-Sophie Wesse, Ann Vandevelde, Katleen Verdonck, Oscar Mammoliti, Tzyh-Chang Hwang, Kathleen Sonck, Pieter Stouten, Andrew M. Swensen, Mia Jans, Jan Van der Schueren, Luc Nelles, Martin Andrews, Katja Conrath
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
There is still a high unmet need for the treatment of most patients with cystic fibrosis (CF). The identification and development of new Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulators is necessary to achieve higher clinical ben
Externí odkaz:
https://doaj.org/article/99852fe337bc4182a943b73d103f71f5
Autor:
Dominique Lambin, Katja Conrath, Tom De Munck, Ann De Blieck, Hans Kelgtermans, Steven Emiel Van Der Plas, Marlon D. Cowart, Christel Jeanne Marie Menet, Sebastien Dropsit, Caroline Joannesse, Oscar Mammoliti, Sebastien Laurent Xavier Martina, Maarten Gees, Giovanni Tricarico, Martin James Inglis Andrews, Anne-Sophie Wesse
Publikováno v:
Journal of Medicinal Chemistry. 64:343-353
Cystic fibrosis (CF) is a life-threatening recessive genetic disease caused by mutations in the gene encoding for the cystic fibrosis transmembrane conductance regulator (CFTR). With the discovery of Ivacaftor and Lumacaftor, it has been shown that a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95c3164798d3ba2edd8da65585ae94bc
https://doi.org/10.1021/acs.jmedchem.0c01796
https://doi.org/10.1021/acs.jmedchem.0c01796
Autor:
Graeme Milligan, Luke Jonathan Alvey, Annick Hagers, Thierry Christophe, Emanuelle Wakselman, Luc Nelles, Line Oste, Steve De Vos, Ann Vandevelde, Katja Conrath, Laurent Saniere, Stephen Robert Fletcher, Laura Jenkins, Sandrine Le Tallec, D. Merciris, Pierre Deprez, Roland Blanque, C. Cottereaux, Romain Luc Marie Gosmini, Ellen van der Aar, Cécile da Costa, Sonia Dupont, Thi Thu Trang Mai, Vanessa Quenehen, Labeguere Frederic Gilbert, Philippe Clément-Lacroix, Florilène Soulas, Reginald Brys, Gregory John Robert Newsome, Nele Vandervoort, Amynata Tirera
Publikováno v:
Journal of Medicinal Chemistry. 63:13526-13545
GPR84 is a medium chain free fatty acid-binding G-protein-coupled receptor associated with inflammatory and fibrotic diseases. As the only reported antagonist of GPR84 (PBI-4050) that displays relatively low potency and selectivity, a clear need exis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a8f803bd9662806c89d70fe1a829f85
https://doi.org/10.1021/acs.jmedchem.0c00272
https://doi.org/10.1021/acs.jmedchem.0c00272
Autor:
Sivagurunathan Sutharsan, Arian Pano, Eva Santermans, Olivier Van de Steen, Katja Conrath, Wolfgang Gleiber, Sam Corveleyn, Nancy Van Osselaer, Susan Bellaire, Axel Kempa, Carsten Schwarz, Silke van Koningsbruggen-Rietschel, K. Muller, Rainald Fischer, Dieudonné Bwirire, Andreas Hector
Publikováno v:
Journal of Cystic Fibrosis. 19:292-298
Background Triple combinations of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators demonstrate enhanced clinical efficacy in CF patients with F508del mutation, compared with modest effects of dual combinations. GLPG2737 was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2526cad6c109745d33aeb24e5489d6dd
https://doi.org/10.1016/j.jcf.2019.09.006
https://doi.org/10.1016/j.jcf.2019.09.006
Autor:
Herman de Kock, D. Kanters, Florence Namour, Katja Conrath, Olivier Van de Steen, Pavel Drevinek, Edward F. McKone, Nico Derichs, Jane C. Davies, Silke van Koningsbruggen-Rietschel, Lisa Allamassey
Publikováno v:
Journal of Cystic Fibrosis. 18:693-699
Background Investigation of novel cystic fibrosis transmembrane conductance regulator (CFTR) potentiators, such as GLPG1837, for CF patients with gating mutations is challenging as trials require patients to withhold ivacaftor, the current standard o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf42728e2a2fda39c8b21e41c446446d
https://doi.org/10.1016/j.jcf.2019.05.006
https://doi.org/10.1016/j.jcf.2019.05.006
Autor:
Jianguo Chen, Ashvani K. Singh, Yao Li, Katja Conrath, Jyoti Sharma, Emily Falk Libby, Li Ping Tang, Ning Peng, Steven M. Rowe, Venkateshwar Mutyam
Publikováno v:
American Journal of Respiratory Cell and Molecular Biology
Am J Respir Cell Mol Biol
Am J Respir Cell Mol Biol
Premature-termination codons (PTCs) in CFTR (cystic fibrosis [CF] transmembrane conductance regulator) result in nonfunctional CFTR protein and are the proximate cause of ∼11% of CF-causing alleles, for which no treatments exist. The CFTR corrector
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b834e3264c71cea70c8d6d3340745e66
https://pubmed.ncbi.nlm.nih.gov/33705685
https://pubmed.ncbi.nlm.nih.gov/33705685
Autor:
Frédéric, Labéguère, Sonia, Dupont, Luke, Alvey, Florilène, Soulas, Gregory, Newsome, Amynata, Tirera, Vanessa, Quenehen, Thi Thu Trang, Mai, Pierre, Deprez, Roland, Blanqué, Line, Oste, Sandrine, Le Tallec, Steve, De Vos, Annick, Hagers, Ann, Vandevelde, Luc, Nelles, Nele, Vandervoort, Katja, Conrath, Thierry, Christophe, Ellen, van der Aar, Emanuelle, Wakselman, Didier, Merciris, Céline, Cottereaux, Cécile, da Costa, Laurent, Saniere, Philippe, Clement-Lacroix, Laura, Jenkins, Graeme, Milligan, Stephen, Fletcher, Reginald, Brys, Romain, Gosmini
Publikováno v:
Journal of medicinal chemistry. 63(22)
GPR84 is a medium chain free fatty acid-binding G-protein-coupled receptor associated with inflammatory and fibrotic diseases. As the only reported antagonist of GPR84 (PBI-4050) that displays relatively low potency and selectivity, a clear need exis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dca817b6050468a00027ab8ce9b149c4
https://pubmed.ncbi.nlm.nih.gov/32902984
https://pubmed.ncbi.nlm.nih.gov/32902984
Autor:
Sebastien Dropsit, Pieter F. W. Stouten, Linda Tomaskovic, Thierry Christophe, Ellen van der Aar, Maarten Gees, Luc Nelles, Mia Jans, Monica Borgonovi, Evelyne M. Quinton, Katja Conrath, Jan Van Der Schueren, Caroline Joannesse, Hans Kelgtermans, Martin James Inglis Andrews, Sebastien Laurent Xavier Martina, Oscar Mammoliti, Ann De Blieck, Steven Emiel Van Der Plas, Tom De Munck
Publikováno v:
Journal of Medicinal Chemistry. 61:1425-1435
Cystic fibrosis (CF) is caused by mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR). With the discovery of Ivacaftor and Orkambi, it has been shown that CFTR function can be partially restored by administering o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc1598dc3e22fb401aa0908c21814b75
https://doi.org/10.1021/acs.jmedchem.7b01288
https://doi.org/10.1021/acs.jmedchem.7b01288